Research programme: nanoparticle radiotherapeutic conjugates - Elucida Oncology
Latest Information Update: 01 Apr 2021
At a glance
- Originator Elucida Oncology
- Class Antineoplastics; Drug conjugates; Immunoconjugates; Radioisotopes
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 11 Mar 2021 Nanoparticle radiotherapeutic conjugates are available for licensing as of 11 Mar 2021. https://www.elucidaoncology.com/our-science/pipeline
- 11 Mar 2021 Preclinical trials in Cancer in USA (Parenteral)